Two new independent studies in peer-reviewed journals point to important trends in TAVR. Neither mention Anteris directly, but both speak to the scientific basis of CEO Wayne Paterson’s regular talking points.

1. The first speaks to the importance of durability in TAVR. It raises issues and problems that DurAVR solves - https://www.ahajournals.org/doi/10.1161/JAHA.125.041505
2. The second is a review of SAVR vs TAVR and the closing of the gap in clinical outcomes between the two. The inference is that the less invasive — and more financially lucrative — TAVR is the trending option (providing there is durability) - https://journals.lww.com/jpbs/fulltext/2025/06002/tavi_through_the_years__a_systematic_review_of.19.aspx

@PabloEskyBruh I know you follow this one very closely hence thought I'd come to you if you had/have any info as to why the sp has continued to fall?